Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx, or larynx~  * SCC of the base of the tongue, pharynx, larynx, or hypopharynx are eligible provided additional biopsy tissue has been already saved in the Tumor Tissue Core Laboratory for research purposes~ * SCC of the oral cavity or tonsils are eligible only if they already have or agree to have additional biopsies of tumor with adjacent normal tissue available for molecular studies~* Candidate for surgical treatment with an established date for surgery with ≥ a 15 day window of opportunity~* Measurable disease by CT scan or MRI~* No nasopharyngeal carcinoma~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status 0-2~* ANC \> 1,500/µL~* Platelet count \> 100,000/µL~* Total bilirubin \< 1.5 mg/dL~* AST/ALT \< 2 times upper limit of normal~* Creatinine \< 1.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements~ * Significant history of uncontrolled cardiac disease (i.e., uncontrolled hypertension, unstable angina, or myocardial infarction within the past 3 months)~ * Uncontrolled congestive heart failure~ * Cardiomyopathy with decreased ejection fraction~* History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on chest CT scan~* Clinically significant ophthalmologic abnormalities~* HIV positivity~PRIOR CONCURRENT THERAPY:~* More than 1 year since prior chemotherapy, biologic therapy, or hormonal therapy~* No prior radiotherapy or chemotherapy for this tumor~* No prior EGFR inhibitors~* No concurrent grapefruit or grapefruit juice~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).